Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1696 - Influence of comorbidities on clinical outcome in patients (pts) receiving chemotherapy (CT) + bevacizumab (BEV) for primary advanced ovarian cancer (OC)

Date

09 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Cancer in Special Situations;  Ovarian Cancer

Presenters

Hannah Woopen

Citation

Annals of Oncology (2017) 28 (suppl_5): v330-v354. 10.1093/annonc/mdx372

Authors

H. Woopen1, P. Wimberger2, A. Mustea3, G. Oskay-Oezcelik4, M. Keller5, R. Richter6, J. Harde7, S. Klawitter8, A. Wegenaer9, O. Tomé10, J. Sehouli6

Author affiliations

  • 1 Department Of Gynecology And Gynecologic Oncology, Charité Campus Virchow Klinikum, 13353 - Berlin/DE
  • 2 Gynecology And Obstetrics, Carl-Gustav-Carus University Dresden TU Dresden, Dresden/DE
  • 3 Gynecology, University Medicine Greifswald, Greifswald/DE
  • 4 Gynecologic Oncology, Praxisklinik Krebsheilkunde fuer Frauen, Berlin/DE
  • 5 C/o Charité Medical University Of Berlin, North-Eastern German Society of Gynaecological Oncology (NOGGO e.V.), Berlin/DE
  • 6 Department Of Gynecology And Gynecologic Oncology, Charité Campus Virchow Klinikum, Berlin/DE
  • 7 Statistics, Data Management And Medical Informatics, iOMEDICO AG, Freiburg/DE
  • 8 Biostatistics And Epidemiology, Roche Pharma AG, Grenzach-Wyhlen/DE
  • 9 Medical Affairs, Roche Pharma AG, Grenzach-Wyhlen/DE
  • 10 Department Of Gynecology, St. Vincentius-Kliniken, Karlsruhe/DE
More

Resources

Abstract 1696

Background

Using interim data from the single-arm non-interventional OTILIA study (NCT01697488; NOGGO) of front-line BEV + CT for OC in routine practice, we explored the impact of pre-existing comorbidities on clinical outcome.

Methods

Pts with FIGO stage IIIB–IV OC received front-line BEV + CT according to the EU label. Adverse events (AEs; CTCAE v4.0) were recorded at each cycle. Post hoc analyses explored safety and effectiveness in subgroups of pts with diabetes mellitus, ongoing hypertension (HTN) or cardiovascular (CV) comorbidities (coronary heart disease, heart failure, arrhythmia, ongoing HTN, thromboembolic event).

Results

As of 31 Jan 2017, data were available for 808 of 1190 planned pts. Comorbidities were more common in pts aged ≥70 (n = 382) than

Conclusions

In OTILIA, pts with comorbidities had similar PFS to the overall population, despite older age and worse ECOG PS. Grade 3/4 AEs were slightly more common, particularly in pts with diabetes mellitus, but did not lead to treatment discontinuation. These post hoc analyses suggest that with appropriate care, BEV is an option in pts with comorbidities.

Clinical trial identification

NCT01697488

Legal entity responsible for the study

Roche Pharma AG

Funding

Roche Pharma AG

Disclosure

H. Woopen: Membership on advisory board or board of directors: Roche Pharma AG. P. Wimberger: Membership on advisory board or board of directors: Roche, Novartis, Amgen, AstraZeneca, MSD, TEVA, Pharma Mar, Fresenius Biotech; Corporate-sponsored research: Roche, Novartis, Amgen, Fresenius Biotech, MSD. A. Mustea: Membership on advisory board or board of directors: Roche. S. Klawitter, A. Wegenaer: Employment: Roche Pharma AG. J. Sehouli: Membership on advisory board or board of directors: AstraZeneca, Roche, OBI Pharma, Pfizer, Clovis, NovoCure. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.